Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M99,974Revenue $M16,385Net Margin (%)12.6Z-Score0
Enterprise Value $M99,975EPS $1.5Operating Margin %11.3F-Score0
P/E(ttm))50.3Cash Flow Per Share $2.8Pre-tax Margin (%)15.0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %-2.8Quick Ratio0Cash flow > EarningsN
Price/Sales6.35-y EBITDA Growth Rate %-23.7Current Ratio0Lower Leverage y-yN
Price/Cash Flow11.7y-y EBITDA Growth Rate %-25.4ROA % (ttm)6.8Higher Current Ratio y-yN
Dividend Yield %2.4Insider Buy (3m)0ROE % (ttm)15.9Less Shares Outstanding y-yN
Payout Ratio %88.0Shares Outstanding M1,659ROI % (ttm)5.7Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYKen Fisher 2014-12-31 Reduce$48.92 - $61.3
($56.42)
$ 60.277%Reduce -39.96%30,739
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 60.2721%Add 6.31%38,480,761
BMYRay Dalio 2014-09-30 Buy $47.86 - $51.96
($49.97)
$ 60.2721%New holding, 10228 sh.10,228
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 60.2721%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 60.2722%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 60.2722%New holding, 89363 sh.89,363
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 60.2722%Add 216.1%49,732
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 60.2722%Sold Out0
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 60.2713%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 60.2713%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 60.2713%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 60.2713%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 60.2713%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 60.2718%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 60.2738%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 60.2738%Reduce -48.95%28,300
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 60.2738%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 60.2739%Add 13.32%20,338,461
BMYGeorge Soros 2013-06-30 Buy 0.05%$39.68 - $47.68
($43.41)
$ 60.2739%New holding, 100000 sh.100,000
BMYJean-Marie Eveillard 2013-06-30 Add0.01%$39.68 - $47.68
($43.41)
$ 60.2739%Add 302.66%66,520
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Vanguard Health Care Fund 2014-12-3139,056,3612.355.4+1.5%
BMY Brian Rogers 2014-12-316,264,8000.381.3
BMY Ken Fisher 2014-12-3130,73900-39.96%
BMY Ray Dalio 2014-09-3010,22800New Buy
BMY Dodge & Cox 2014-09-3090,4280.010+14.58%
BMY Vanguard Health Care Fund 2014-09-3038,480,7612.325+6.31%
BMY Mario Gabelli 2014-09-30700,2550.040.19+3.79%
BMY Ken Fisher 2014-09-3051,20100.01+2.95%
BMY Irving Kahn 2014-09-3027,65000.23
BMY Jean-Marie Eveillard 2014-09-3014,49200
BMY Ronald Muhlenkamp 2014-09-30212,4850.012-0.13%
BMY Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTOCEO 2014-12-05Sell75,000$60.31-0.07view
ANDREOTTI LAMBERTOCEO 2014-11-05Sell75,000$57.794.29view
ANDREOTTI LAMBERTOCEO 2014-10-24Sell50,000$5313.72view
CORNELIUS JAMES MDirector 2014-10-15Sell100,000$48.9223.2view
ANDREOTTI LAMBERTOCEO 2014-10-06Sell50,000$50.9918.2view
Cuss Francis MEVP & CSO 2014-09-16Sell63,667$50.7718.71view
Caforio GiovanniCOO 2014-09-15Sell26,691$49.8720.85view
Caldarella Joseph CSVP & Controller 2014-09-10Sell7,415$51.0318.11view
ANDREOTTI LAMBERTOCEO 2014-09-08Sell50,000$51.0518.06view
von Autenried PaulSVP, Enterp. Services & CIO 2014-08-19Sell20,000$49.8920.81view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
    Feeling Good With This Med Company Jan 20 2015 
    mom Dec 27 2014 
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
    A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
    Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
    A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
    Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company Oct 19 2014 
    The Six Types of Winning Stocks Oct 17 2014 
    Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 


    More From Other Websites
    Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog Jan 30 2015
    US profitability: the rich list Jan 30 2015
    U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and... Jan 29 2015
    5:20 pm Bristol-Myers confirms that the FDA has approved Evotaz (atazanavir 300 mg and cobicistat... Jan 29 2015
    U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and... Jan 29 2015
    Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of... Jan 29 2015
    Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of... Jan 29 2015
    Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of... Jan 29 2015
    Company News for January 28, 2015 - Corporate Summary Jan 28 2015
    Drug Firms Report Good Q4, But Outlook Cloudy Jan 27 2015
    Cramer: I've never seen anything like this Jan 27 2015
    Strong Dollar Means Flabby Outlook For Some Overseas Jan 27 2015
    Cancer Drugs Boost Bristol-Myers Sales Jan 27 2015
    Midday movers: Lockheed Martin, Plantronics & more Jan 27 2015
    Bristol-Myers Squibb (BMY) Stock Falls Today on Weak Guidance Jan 27 2015
    Pfizer Edges Ahead On Q4, Even As Forecast Falls Short Jan 27 2015
    Bristol-Myers Beats on Q4 Earnings, 2015 View Disappoints - Analyst Blog Jan 27 2015
    Bristol-Myers says strong dollar drags on 2015 outlook Jan 27 2015
    Bristol-Myers issues cautious 2015 forecast due to strong dollar Jan 27 2015
    Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues - Tale of the Tape Jan 27 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK